SAFC will invest $29 million to expand its drug substance capabilities in high-potency biologics at the Sigma-Aldrich facility in Jerusalem, Israel. The site expansion will allow SAFC Pharma to provide process development and cGMP manufacturing for large-scale, high-potency, toxic or hazardous drug substances (large molecule HPAPIs). The 50,000-sq.-ft. high-potency fermentation expansion will focus on production of secondary metabolites (antibiotic-like molecules), cytotoxins and large-mole...